These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9562828)

  • 21. Valsartan and the kidney: present and future.
    Mann JF
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S37-40; discussion S41-3. PubMed ID: 10028953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
    Sidorenko BA; Preobrazhenskiĭ DV; Stetsenko TM; Tarykina EV; Tsurko VV
    Kardiologiia; 2003; 43(2):88-95. PubMed ID: 12891278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valsartan and the kidney: review of preclinical and clinical data.
    Ruilope LM
    Adv Ther; 2001; 18(2):57-66. PubMed ID: 11446269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Stumpe KO
    Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dosage equivalents of AT1-receptor antagonists available in Germany].
    Dominiak P; Häuser W
    Dtsch Med Wochenschr; 2003 Oct; 128(44):2315-8. PubMed ID: 14593575
    [No Abstract]   [Full Text] [Related]  

  • 26. Angiotensin II receptor antagonists in the treatment of hypertension.
    Kaplan NM
    Am Fam Physician; 1999 Sep; 60(4):1185-90. PubMed ID: 10507747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VALUE in hypertension treatment.
    Berk BC; Bisognano JD
    Curr Hypertens Rep; 2004 Dec; 6(6):411-3. PubMed ID: 15527682
    [No Abstract]   [Full Text] [Related]  

  • 28. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    Cohn JN
    Am J Cardiol; 2002 Nov; 90(9):992-3. PubMed ID: 12398968
    [No Abstract]   [Full Text] [Related]  

  • 29. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
    Ramahi TM
    Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hope in Life and Value of blood pressure control.
    Ruilope LM; Segura J
    J Hypertens; 2004 Dec; 22(12):2265-6. PubMed ID: 15614017
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of angiotensin II antagonists in hypertension.
    Spence JD
    Can J Cardiol; 1999 Nov; 15 Suppl F():33F-5F. PubMed ID: 10579750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
    Martin J; Krum H
    Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
    Bunt T
    Clin Ther; 1999 Mar; 21(3):611-2. PubMed ID: 10321426
    [No Abstract]   [Full Text] [Related]  

  • 34. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M
    Heart Fail Monit; 2002; 2(3):85-7. PubMed ID: 12634889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Angiotensin receptor blockers--significance for the therapy of hypertension].
    Magometschnigg D
    Wien Med Wochenschr; 2001; 151(7-8):153-6. PubMed ID: 11450162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II antagonism in clinical practice: experience with valsartan.
    McInnes GT
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S29-32; discussion S41-3. PubMed ID: 10028951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Coca A; Giner V
    Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers.
    van Veldhuisen DJ; Voors AA
    Eur Heart J; 2000 Jan; 21(1):14-6. PubMed ID: 10610738
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.